Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
作者： Stephan H. Schirmer , Magnus Baumhäkel , Hans-Ruprecht Neuberger , Stefan H. Hohnloser , Isabelle C. van Gelder
DOI: 10.1016/J.JACC.2010.09.017
关键词:
摘要: Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for ischemic stroke. Antithrombotic therapy using aspirin or vitamin K antagonists (VKA) currently prescribed prevention stroke in patients with AF. A narrow therapeutic range need of regular monitoring its anticoagulatory effect impair effectiveness safety VKA, causing alternative anticoagulant drugs. Recently developed anticoagulants include direct thrombin such as dabigatran Xa inhibitors rivaroxaban, apixaban, betrixaban, edoxaban. Currently, data from phase III clinical trial are available only, which show antagonist to be at least noninferior efficacy VKA systemic embolism This review focuses on current advances development directly acting oral drugs their potential replace class
narcis.nl
elsevier.com
researchgate.net 参考文章(86)
Rivaroxaban-once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF Study American Heart Journal. ,vol. 159, pp. 340- 347 ,(2010) , 10.1016/J.AHJ.2009.11.025
, Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. ,vol. 119, pp. 2877- 2885 ,(2009) , 10.1161/CIRCULATIONAHA.108.832139
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. ,vol. 293, pp. 690- 698 ,(2005) , 10.1001/JAMA.293.6.690
Carlos A Salazar, German Malaga, Giuliana Malasquez, Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement Cochrane Database of Systematic Reviews. ,vol. 2010, ,(2010) , 10.1002/14651858.CD005981.PUB2
C. Jacobshagen, D. Westermann, C. Holubarsch, M. Böhm, Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more. Clinical Research in Cardiology. ,vol. 99, pp. 337- 344 ,(2010) , 10.1007/S00392-010-0154-6
Galina S. Bogatkevich, Anna Ludwicka-Bradley, Richard M. Silver, Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis & Rheumatism. ,vol. 60, pp. 3455- 3464 ,(2009) , 10.1002/ART.24935
R.J. Friedman, O.E. Dahl, N. Rosencher, J.A. Caprini, A.A. Kurth, C.W. Francis, A. Clemens, S. Hantel, J.M. Schnee, B.I. Eriksson, Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials Thrombosis Research. ,vol. 126, pp. 175- 182 ,(2010) , 10.1016/J.THROMRES.2010.03.021
Michael D. Ezekowitz, Paul A. Reilly, Gerhard Nehmiz, Timothy A. Simmers, Rangadham Nagarakanti, Kambiz Parcham-Azad, K. Erik Pedersen, Dominick A. Lionetti, Joachim Stangier, Lars Wallentin, Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). American Journal of Cardiology. ,vol. 100, pp. 1419- 1426 ,(2007) , 10.1016/J.AMJCARD.2007.06.034
John W Eikelboom, Martin O'Donnell, Salim Yusuf, Rafael Diaz, Greg Flaker, Robert Hart, Stefan Hohnloser, Campbell Joyner, Jack Lawrence, Prem Pais, Janice Pogue, David Synhorst, Stuart J Connolly, None, Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment American Heart Journal. ,vol. 159, pp. 348- 353 ,(2010) , 10.1016/J.AHJ.2009.08.026